BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Position Decreased by Calamos Advisors LLC

Calamos Advisors LLC cut its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 68.2% in the fourth quarter, Holdings Channel reports. The firm owned 33,021 shares of the medical equipment provider’s stock after selling 70,827 shares during the period. Calamos Advisors LLC’s holdings in BioLife Solutions were worth $857,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp raised its stake in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after acquiring an additional 18,473 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after acquiring an additional 262,504 shares during the last quarter. Curi RMB Capital LLC increased its holdings in shares of BioLife Solutions by 0.5% during the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after acquiring an additional 2,283 shares during the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in shares of BioLife Solutions by 2.9% during the 3rd quarter. Eagle Asset Management Inc. now owns 352,897 shares of the medical equipment provider’s stock valued at $9,221,000 after acquiring an additional 10,091 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Stock Performance

BLFS opened at $26.72 on Thursday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -25.21 and a beta of 1.91. The stock’s 50 day moving average price is $26.81 and its two-hundred day moving average price is $25.16. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12-month low of $14.50 and a 12-month high of $29.55.

Analyst Ratings Changes

BLFS has been the topic of a number of analyst reports. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Craig Hallum increased their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Benchmark reissued a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp increased their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and an average price target of $29.43.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,278 shares of company stock valued at $1,199,987 in the last 90 days. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.